Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) has developed new silicone products for personal care applications as part of its silicon chemistry-driven solutions (Shin-Etsu Silicones Solution-EngineeringTM). In the personal care industry, research and development activities are being carried out on various themes such as addressing diverse consumer demand and environmental issues and improving production efficiency. In response...

NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of...

CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (D...

KAYTUS, a leading provider of end-to-end AI and liquid cooling solutions, has announced the release of the enhanced KSManage V2.3, its advanced device management platform for AI data centers. The latest version introduces expanded monitoring and control capabilities tailored for GB200 and B200 systems, including integrated liquid cooling detection features. Leveraging intelligent automation, KSManage V2.3 enables AI data centers to operate with greater precision, efficiency, and sustainability,...

Aksia is pleased to announce the addition of three distinguished professionals to our team: Sebastiaan van den Berg, Christopher Schelling, and Benjamin Parks. Their extensive experience and expertise will further strengthen Aksia's capabilities and commitment to delivering exceptional service to our clients. Sebastiaan van den Berg joins Aksia as a Partner on the Private Equity team. Sebastiaan will work closely with Aksia’s Pan-Alts and Private Equity teams to support the Firm’s EMEA clients...

FlexTrade Systems, a global leader in multi-asset execution and order management systems, and Kepler Cheuvreux, a leading independent European financial services company through its KCx execution services, today announced the availability of KCx’s sophisticated analytical suite directly from FlexTrade’s AI assistant, FlxAI, to deliver intelligent, high-value insights into client workflows. With rapid advancements in AI, large language models are reshaping how financial firms interact with data...

Horizon3.ai, the company behind the NodeZero® Autonomous Security Platform, today announced a $100 million Series D funding round led by NEA, with participation from SignalFire, Craft Ventures and 9Yards Capital. As part of the investment, Lila Tretikov, Partner and Head of AI Strategy at NEA and former Deputy CTO of Microsoft, will join the Horizon3.ai Board of Directors. “Over the past four years, we’ve proven that using AI to hack companies isn’t science fiction—it’s real, and it’s deliver...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Thousands of people with CF across the EU may now benefit from this new, once-daily medicine, which has demonstrated further improvement in CFTR pr...

IFF (NYSE: IFF) announced today the commencement of tender offers to purchase for cash certain of its outstanding series of notes listed in the tables below (collectively, the “Notes”) for an aggregate purchase price, excluding accrued and unpaid interest, of up to $1.8 billion. Pool 1 Tender Offers Pool 1 Maximum Amount: $1.0 billion(1(a)) Title of Security CUSIP/ISIN Principal Amount Outstanding(in millions) Acceptance Priority Level(2) Series Tender Cap(3) U.S. Treas...